Oculis Holding AG (OCS) Capital Expenditures Growth (1y) (2023 - 2026)

Oculis Holding AG (OCS) Capital Expenditures Growth (1y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex Growth (1y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 38.18%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -27.93%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 227.76%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 0.57%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Alnylam Pharmaceuticals 35.71 Bn 32.70 Bn 959.66 Mn 143.40%

Historic Data

Download Data
DateValue
Mar 31, 2026 38.18%
Dec 31, 2025 26.93%
Sep 30, 2025 12.79%
Dec 31, 2024 -1,054.33%
Sep 30, 2024 -726.32%
Dec 31, 2023 99.65%
Sep 30, 2023 95.69%